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Refresher course: oligometastases
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The word metastasis is originally a Greek word meaning “dis-
placement”, from meta, “next” and stasic¸, statis, “placement”.
Cancer treatment and survival are determined, mainly, by
whether or not a cancer remains localized or spreads to other
locations in the body. Cancer staging describes the extent of
the tumor and it is critical because treatment is based on
this parameter. Staging systems for cancer have evolved over
time and continue to do so. The universally accepted staging
system for solid tumors (except for those located in the cen-
tral nervous system) is that of the UICC (and AJCC) based on
the TNM system, initially developed by Pierre Denoix between
1943 and 1952). TNM combinations correspond to one of ﬁve
stages: Stage 0 for in situ, Stages I–III for loco-regional disease
and Stage IV for metastatic disease.
The “N” category deﬁnes localized spreading to regional
lymph nodes near the primary tumor and is not normally
counted as metastasis, although distant metastatic ocur-
rences worsens the prognosis. In stage IV there is evidence of
distant metastases (M1) and traditionally was associated with
a 0% long term survival (not curable). Although diseases arise
in nature, their diagnostic categories are generated by man
in ways that are useful, so this classiﬁcation is occasionally
suffering modiﬁcations and has exceptions to adjust to mod-
ern data that are arising from the new treatments. Currently,
for example, supraclavicular lymph node spread is not con-
sidered now a metastasis (it’s considered a N3 disease) and
metastatic thyroid papillary carcinomas are not necessarily
stage IV anymore.
The traditional concept of incurability of stage IV, and
the idea that metastatic patients have terminal disease is
changing. In 1995, Hellman and Weischselbaum proposed a
paradigm shift, introducing the notion of “oligometastases”.
They hypothesize that in some patients with a limited num-
ber of clinically detectable metastatic tumors, the extent of
disease exists in a transitional state between localized and
widespread disease.
There is evidence suggesting that local control of
oligometastases may yield improved systemic control and
prolong disease-free survival. Improvement in local therapies
such as surgery, radiotherapy or radiofrequency ablation for
theoligometastatic sites could thus improvepatient’s survival.
Arguments to support oligometastatic as a different
clinical stage (maybe M0, M1 for one metastasis, M2 for
oligometastatic and M3 disseminated with no possibility for
local control, or IVA vs IVB?) could include:
- Curative intent-treatments are possible
- Few lesions with usually poor growth capacity
- Reﬂects cancer cells with limited metastatic capability or
limited by chemotherapy systemic treatment
- Is the early detection of a potentially larger disease
However, there are also questions to be solved in the
oligometastaic setting:
Should there be an operational max number cut-off point?
(for example: less than 5 or 8macroscopic lesions) Or consider
the number and the total volume?
- Should there be an operational max metastatic volume cut-
off point?
- What is the real prevalence of oligometastatic disease? Does
it depend on the quality and type of diagnostic explorations
done?
- Does their outcome depend on their early diagnosis?
- Is there indication to treat all metastasis simultaneously or
some do have priority?
- Which is the most convenient follow-up?
- Are there any prognostic or risk factors?
- What’s the biology of all this? Given that there’s no random-
ized/universal seeding and there appears to be some target
tissue (soil) interaction/local growth factors. The dormancy
and abscopal effects sometimes observed have not been
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clearly explained, genetic instability of the primary and the
metastatic tumors might be taken into account. Anatomic
and mechanic factors (cascade/step by step dissemination)
also appear to play a role. . .
Current data shows that oligometastatic patients are a very
heterogeneous group and that there are not enough reports on
their long term follow-up. Local treatments less invasive than
surgery seem to be gaining a place. Undoubtedly, this partic-
ular clinical situation would beneﬁt from a multidisciplinary
approach.
Oligometastases treatment examples in use and with
proven results include:
- Resection of liver metastases in colon tumors (with or
without previous chemotherapy for cito-reduction and
resectability improvement)
- Resection or SBRT of lung metastases from multiple pri-
maries
- Adrenal gland resection in lung tumors
- Brain metastases surgery or radiosurgery
- Solitary bone metastases SBRT.
The mayor relevance for oligometastasis is the better local
treatments as there are improving radiotherapy techniques,
ﬁrst with radiosurgery for multiple brain metastasis and later
with SBRT for systemic metastasis, mainly lung, spinal and
liver. As previous historic improvement in surgery devel-
opment for better results, also radiotherapy improvements
modify treatment with better local control and prognosis for
oligometastatic patients.
It is not the same the prognostic for a breast cancer
patient triple negative with oligometastatic brain metas-
tasis or with Her2 positivity. The SBRT treatment for
oligometastatic lung metastasis has nearly 100% local con-
trol, but which patients will improve survival and quality of
life?
The paradigm is always how to classify the oligometastatic
patients and how to decide the always necessary multidisci-
plinary treatment.
